These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20003034)

  • 1. Mortality after failure of antiretroviral therapy in sub-Saharan Africa.
    Keiser O; Tweya H; Braitstein P; Dabis F; MacPhail P; Boulle A; Nash D; Wood R; Lüthi R; Brinkhof MW; Schechter M; Egger M;
    Trop Med Int Health; 2010 Feb; 15(2):251-8. PubMed ID: 20003034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
    Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
    J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring.
    Gsponer T; Petersen M; Egger M; Phiri S; Maathuis MH; Boulle A; Musondad P; Tweya H; Peter K; Chi BH; Keiser O;
    AIDS; 2012 Jan; 26(1):57-65. PubMed ID: 22089376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
    De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
    Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
    AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti.
    Charles M; Leger PD; Severe P; Guiteau C; Apollon A; Gulick RM; Johnson WD; Pape JW; Fitzgerald DW
    J Int AIDS Soc; 2012 Jun; 15(2):17375. PubMed ID: 22713258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
    Schoffelen AF; Wensing AM; Tempelman HA; Geelen SP; Hoepelman AI; Barth RE
    PLoS One; 2013; 8(3):e58526. PubMed ID: 23505529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps.
    Murphy RA; Court R; Maartens G; Sunpath H
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1181-1184. PubMed ID: 28793781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
    May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
    Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
    Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
    AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.